Agilon Health Reports First Quarter 2025 Results: A Mixed Performance Amid Market Challenges

Agilon Health, Inc. (NYSE: AGL), a key player in transforming healthcare for senior patients, released its financial results for the first quarter ended March 31, 2025, showcasing a complex landscape marked by a decline in membership, a drop in revenue, but a notable recovery in net income.

Steven Sell, CEO of Agilon Health, expressed optimism regarding the company’s performance, stating, “I’m encouraged by our first quarter results and the progress we are making on key initiatives to drive improved operating performance.” He emphasized the commitment to Agilon’s Total Care Model, which aims to enhance patient health outcomes while delivering cost-effective care.

As of March 31, 2025, Agilon's total members on its platform decreased to 605,000, down from 654,000 a year earlier. This includes 491,000 Medicare Advantage members and 114,000 ACO REACH model beneficiaries, reflecting a year-over-year decline of 6% and 13%, respectively. The decrease in membership is attributed to previously announced market exits.

The company reported total revenue of $1.53 billion, a 4% decrease compared to $1.60 billion in the first quarter of 2024. This decline was primarily due to the impact of market exits, despite some growth in new markets.

Contrastingly, Agilon achieved a net income of $12 million for the first quarter of 2025, a noteworthy turnaround from a net loss of $6 million in the same period last year. Gross profit fell to $51 million, down 32% from $75 million in Q1 2024, while the medical margin decreased to $128 million, reflecting a 19% drop year-over-year.

Adjusted EBITDA stood at $21 million, down from $29 million in Q1 2024. The first quarter’s medical margin was impacted by a negative $22 million net effect from prior year claims, which included $7 million from exited markets, compared to a negative $9 million impact in Q1 2024.

As of March 31, 2025, Agilon's balance sheet showed cash, cash equivalents, and marketable securities totaling $369 million, with total debt remaining low at $35 million. The company also had $25 million in cash associated with its unconsolidated ACO model entities.

Looking ahead, Agilon provided guidance for the second quarter and the full fiscal year of 2025. The company anticipates a range of 485,000 to 515,000 Medicare Advantage members and 105,000 to 115,000 ACO model members for Q2. Total revenue projections are set between $1.435 billion and $1.505 billion for the quarter, with expected medical margins ranging from $50 million to $70 million.

For the full year, Agilon expects total revenues to fall between $5.85 billion and $6.025 billion, alongside medical margins of $275 million to $325 million. The company projects a negative Adjusted EBITDA in the second quarter, ranging from ($35 million) to ($20 million), reflecting ongoing investments in technology and clinical programs aimed at enhancing operational efficiency.

Agilon Health remains focused on long-term growth priorities, emphasizing the importance of its Total Care Model to deliver quality outcomes and cost-effective care. The management acknowledges challenges posed by market exits and elevated medical cost trends, which are expected to persist through 2025.

Agilon Health's first quarter results paint a picture of resilience amid challenges, with a stabilizing net income and strategic investments laying the groundwork for future growth. As the company navigates its current landscape, the emphasis on quality care and operational improvements will be critical in maintaining its position as a trusted partner in the healthcare sector.